Abstract
Two applications claim novel 1,4-bisphenyl-1,4-dihydropyridine derivatives; 2-hydroxy and 2-aminodihydropyridines, respectively. The compounds are claimed to be useful as neutrophil elastase inhibitors and also in the treatment of both chronic obstructive pulmonary disease and myocardial infarction. These compounds represent yet another use of the widely employed 1,4-dihydropyridine privileged structure.